2010
Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial.
Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, Mohamed S, Rao S. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. The Journal Of Clinical Psychiatry 2010, 71: 915-22. PMID: 20361918, DOI: 10.4088/jcp.09m05699gre.Peer-Reviewed Original ResearchConceptsBaseline suicidal ideationHamilton Depression Rating ScaleDepression Rating ScaleSubthreshold depressive symptomsCalgary Depression Rating ScaleDepressive symptomsSuicidal ideationSchizoaffective disorderClinical Global Impressions-SeverityBeck Hopelessness ScaleDSM-IV-diagnosed schizophreniaRating ScaleTreatment-emergent suicidal ideationPlacebo-controlled trialSuicidal ideation measuresItem 3Citalopram augmentationFinal visitPlacebo augmentationSecondary outcomesPrimary outcomeOlder outpatientsInterSePT ScaleCitalopramPlacebo
2008
Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. The Journal Of Clinical Psychiatry 2008, 70: 562-71. PMID: 19192468, DOI: 10.4088/jcp.08m04261.Peer-Reviewed Original ResearchConceptsQuality of lifeSubsyndromal symptomsSchizoaffective disorderOlder patientsOlder outpatientsTreatment groupsRandomized placebo-controlled trialRating ScaleFlexible-dose treatmentSecondary efficacy analysesPlacebo-controlled trialCurrent antipsychotic medicationsDepression Rating ScaleGeneral medical healthHamilton Rating ScaleCalgary Depression Rating ScaleYears of ageDSM-IV schizophreniaCitalopram augmentationAdverse eventsPlacebo augmentationEfficacy analysisAntipsychotic medicationStudy criteriaDimensions of schizophrenia
2004
The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. DOI: 10.1097/01.jam.0000129822.54487.14.Peer-Reviewed Original ResearchLong-term care settingsOlder patientsAtypical antipsychoticsCare settingsNeurodegenerative disordersSide effectsDouble-blind placebo-controlled trialHigh-potency conventional antipsychoticsLong-term care patientsOpen-label studyPlacebo-controlled trialNewer atypical antipsychoticsOlder patient populationUse of quetiapineUse of risperidoneExtrapyramidal side effectsAtypical antipsychotic medicationsConventional antipsychoticsCare patientsTardive dyskinesiaNovel antipsychoticsAntipsychotic medicationPatient populationPsychopharmacologic agentsAgitation symptomsThe Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting
Kasckow J, Mulchahey J, Mohamed S. The Use of Novel Antipsychotics in the Older Patient With Neurodegenerative Disorders in the Long-Term Care Setting. Journal Of The American Medical Directors Association 2004, 5: 242-248. PMID: 15228634, DOI: 10.1016/s1525-8610(04)70130-9.Peer-Reviewed Original ResearchConceptsAtypical antipsychoticsRate of extrapyramidal side effectsHigh-potency conventional antipsychoticsDays of risperidoneAtypical antipsychotic medicationsExtrapyramidal side effectsDay of olanzapineDouble-blind placebo-controlled trialConventional antipsychoticsNovel antipsychoticsAntipsychotic medicationTardive dyskinesiaTreating older patientsPsychopharmacological agentsAgitation symptomsNeurodegenerative disordersAntipsychoticsBehavioral agitationPlacebo-controlled trialOpen-label studyOlder patientsHigh-potencyAripiprazoleOlanzapineRisperidone